ClinicalTrials.gg
CompletedNCT05434663Updated Nov 19, 2026Results posted

Safety Study of Repeat Doses of SUSTOL in Adults

A Phase 4 interventional study of SUSTOL and SUSTOL kit components for administration in Chemotherapy-Induced Nausea and Vomiting (CINV), sponsored by Heron Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Heron Therapeutics · Phase 4, Interventional, and Prevention

How we know

Updated Nov 19, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing granisetron in Vomiting — none open to participants now, none under way, none of them phase 3. Granisetron · Vomiting.

Enrollment
19th of 25
24 · median 60
Started
2022
with 1 other
Phase 4
7 of 25
none open now
Registered
24th of 25
by date
Lead sponsor
1 of 25
Heron Therapeutics

Among the 25 studies testing granisetron in Vomiting, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 4, and was the 24th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

Browse Vomiting studies →

Open to participants now

None of the 25 studies testing granisetron in Vomiting is open now. The open studies under Vomiting, anywhere →

About granisetron

Granisetron: first FDA approval 1993 (KYTRIL), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing granisetron in Vomiting as a file.
02

Study summary

This was a repeat-dose, single-arm, open-label study that evaluated the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

Read the detailed description

This study was a post-marketing requirement (PMR) study with a planned sample size of 300 subjects. The Sponsor stopped the study upon release from the PMR, with 24 subjects having participated.

03

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting (CINV)

Keywords

  • HTX-100
  • APF530
  • injection site reaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has cancer and is scheduled to receive MEC or AC regimen for at least 4 cycles of chemotherapy, and is prescribed SUSTOL for CINV prevention.
  2. Has an performance status of 0 or 1.
  3. Has of greater than 6 months.
  4. Able to receive standardized doses of dexamethasone for the prevention of emesis.
  5. Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study.

Exclusion criteria

Exclusion Criteria:

  1. Has to granisetron, any component of SUSTOL, or any other 5-HT3 Receptor Antagonists.
  2. Severe renal impairment ( [CLcr] \<30 mL/min).
  3. Symptomatic primary or central nervous system (CNS) disease.
  4. Has participated in an interventional clinical study within 30 days of Cycle 1 Day 1.
  5. Investigator assessment that subject would not be a good fit for the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    SUSTOL

    SUSTOL® (granisetron) extended-release injection, for subcutaneous use

    Drug: SUSTOL · Device: SUSTOL kit components for administration

Interventions

  • DrugSUSTOL

    Drug page: GranisetronStudies of GranisetronGranisetron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles. Supplied in commercially available SUSTOL kits.

    Also known as: Granisetron extended-release injection for subcutaneous use

  • DeviceSUSTOL kit components for administration

    Each SUSTOL kit includes 1 sterile glass syringe containing 10 mg granisetron/0.4 mL, 1 sterile 18 Ga 5/8" special thin-walled administration needle, 2 sodium acetate syringe warming pouches, and 1 Point Lok needle protection device.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL

    Proportion of subjects with: • ISR of pain, itching, or swelling with a severity ≥7 AND ADL impact of ≥7 in any ADL domain (physical, social, work/household). OR • ISR of bleeding with ADL impact of ≥7 in any ADL domain (physical, social, work/household), AND 1 of the following: * Severity ≥7 and 4 to 6 bandage changes per day OR * ≥7 bandage changes per day OR * Urgent care/ER visit.

    Time frame: Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneSUSTOL
Started24
Completed18
Not completed6
Withdrew: Carboplatin shortage2
Withdrew: Death1
Withdrew: Noncompliance1
Withdrew: Switch to maintenance treatment1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL

Proportion of subjects with: • ISR of pain, itching, or swelling with a severity ≥7 AND ADL impact of ≥7 in any ADL domain (physical, social, work/household). OR • ISR of bleeding with ADL impact of ≥7 in any ADL domain (physical, social, work/household), AND 1 of the following: * Severity ≥7 and 4 to 6 bandage changes per day OR * ≥7 bandage changes per day OR * Urgent care/ER visit.

Time frame:
Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).
Reported as:
Count of participants · Participants
Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL
ParticipantsSUSTOL
Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL1

Adverse events

Collected over Up to approximately 20 weeks: From the time the subject signed the Informed Consent Form through the final study visit (28 days after the subject's last SUSTOL dose).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SUSTOL1/24 (4.2%)5/24 (20.8%)0/24 (0%)
Most frequent serious events
Most frequent serious events
EventSUSTOL
SepsisInfections and infestations1/24
Septic shockInfections and infestations1/24
COVID-19Infections and infestations1/24
Chest painGeneral disorders1/24
Breast abscessInfections and infestations1/24
Deep vein thrombosisVascular disorders1/24

Baseline characteristics

All subjects who received SUSTOL

Age, Continuous
Age, Continuous(years)SUSTOL
Mean55.6 ± 15.12
Sex: Female, Male
Sex: Female, Male(Participants)SUSTOL
Female15
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SUSTOL
Hispanic or Latino1
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SUSTOL
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American9
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)SUSTOL
United States24
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2023, 16 months.

Results were first posted in Nov 2026, 3 years 2 months after primary completion.

Of 42 phase 4 interventional studies under Vomiting, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 16 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2022 → May 2022, primary completion Oct 2025 → Sep 2023 and completion Oct 2025 → Sep 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2022
First posted
Jun 28, 2022
StartActual
May 13, 2022was Jul 2022
Primary completionActual
Sep 18, 2023was Oct 2025
CompletionActual
Sep 18, 2023was Oct 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Results
Results posted
posted Nov 19, 2026
Start date
Jul 6, 2022→May 13, 2022
Nov 19, 2026
Primary completion
Oct 2025→Sep 18, 2023 (actual)
Nov 19, 2026
Study completion
Oct 2025→Sep 18, 2023 (actual)
Nov 19, 2026
Enrollment
300 (estimated)→24 (actual)
Nov 19, 2026
Interventions
Added Device: SUSTOL kit components for administration. Arms added: SUSTOL; arms removed: Treatment Group
Nov 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of subjects with potential impact of subjectSubjects With Severe Subject-reported ISRs With Significant Impact on ADL in adult subjects with cancer administered SUSTOL.Time frame: 14 days → Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).
Nov 19, 2026
Documents
Show all 1 update
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Results posted
    Start date Jul 6, 2022→May 13, 2022
    Primary completion Oct 2025→Sep 18, 2023 (now actual)
    Study completion Oct 2025→Sep 18, 2023 (now actual)
    Enrollment 300 (estimated)→24 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of subjects with potential impact of subjectSubjects With Severe Subject-reported ISRs With Significant Impact on ADL in adult subjects with cancer administered SUSTOL.Time frame: 14 days → Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).
    Interventions Added Device: SUSTOL kit components for administration. Arms added: SUSTOL; arms removed: Treatment Group
    + 5 other changes: verification date, oversight details, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05434663
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jun 28, 2022
Start date
May 13, 2022
Primary completion
Sep 18, 2023
Completion
Sep 18, 2023
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granisetron

Start the discussion